Archangels - Making The Future

Archangel provides

Financial strength

The syndicate comprises around 100 High Net Worth members who collectively have significant funds available for investment.  Since its formation in 1992, syndicate members have invested in excess of £55m into some 60 early stage companies and for the last 3 years have been investing at the rate of around £10m pa.

The strength of the syndicate is also evident in its ability to fund further rounds of investment in its companies when required provided that the business case remains sound.

Low deal costs

Unlike most other investment bodies, Archangels do not charge the company an arrangement fee for the initial investment.  We also use low cost standard legal agreements which keep the legal fees payable by the company for completion of an investment to a minimum.  There is a modest annual fee to the companies to cover the costs of ongoing monitoring and liaison.

Range of contacts

Our membership and corporate network is extensive, particularly within Scotland but also globally.  We have strong connections with Scottish Enterprise, Banks and other investor groups which give us good access to a range of financial assistance.  We also have very good connections across a range of commercial and professional companies which can provide young companies introductions to help their businesses.  In addition, we encourage interaction between our portfolio companies to share problems and ideas.

Business experience

The Directors of Archangel Informal Investment are all highly experienced business men who are well versed in the particular needs of young companies.  In addition, we have a close network of individuals who will take on the role of non-executive Chairman or Director and add value to specific companies.

Experience of exits

Since 1992, the syndicate has completed a number of successful exits alongside the original founders.  The sale or flotation of a company can be a complex transaction which needs to be handled professionally and sensitively and the experience of the Archangel team in this area can be very valuable.

Patience

One of our investment philosophies is that we concentrate on building strong companies rather than look for early exits before real value has been achieved.  We have no objection to holding investments which can yield satisfactory dividend streams.  Although an eventual exit is usually the goal of both founders and investors, we believe that the best exits are achieved by being patient and waiting for the right deal to come along at the right time.

 

Latest News

Touch Bionics unveils the new i-LIMB Pulse

05 May 2010
Touch Bionics today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the wordl's first commercially available bionic hand. The i-LIMB Pulse is a significant advance for the i-LIMB product line, with a host of enhancements, including pulsing grip strength, software-enabled grip patterns and robust aluminium features for improved strength.

Touch Bionics wins prestigious Queen's Award for innovation

21 Apr 2010
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced it is a winner of the prestigious Queen's Awards for Enterprise with an award in the Innovation category for 2010. The Queen's Awards for Enterprise are the UK's most prestigious awards for business performance.

Bloxx Delivers Web Filtering Excellence at Wellingborough School

21 Apr 2010
School has immediate access to safe internet surfing with Bloxx Web Filtering. Bloxx today announced that Wellingborough School is providing safe Internet access for around 900 users and achieving superior anonymous proxy detection by using Bloxx's real time Web filtering, powered by its patented Tru-View Technology.

Bloxx helps Yorkshire Building Society keep staff safe online

15 Apr 2010
Bloxx the innovator in Web content filtering, announced on 15th April that Yorkshire Building Society is using Bloxx Web filtering to monitor and report on the Web browsing activity of over 2,000 staff, delivering superior protection from imappropriate or productivity impacting content and minimising network security risks.

New "Penicillin" for the 21st Century

01 Apr 2010
Today MGB Biopharma Limited, a late preclinical stage biopharmaceutical company, has commenced operations in Glasgow, UK to develop and commercialise a new class of antibacterial product: DNA Minor Groove Binders.